COPD: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• NRF2 0
• MAPK 0
• NLRP3 0
• PI3K 0
• STAT3 0
• GLP-1 1
• SIRT1 0
• PDE4 0
• AKT 0
• ERK 0
• STING 0
• TP53 0
• TSLP 2
• JAK 0
• TLR4 0
• IL-6 2
• MMP-9 0
• mTOR 0
• PPAR 0
• CFTR 0
• GPX4 0
• IL-17 0
• PD-L1 1
• TNF 0
• VEGF 0
• AMPK 0
• HIF-1 0
• PD-1 0
• SGLT2 0
• EGFR 0
• JNK 0
• COX-2 0
• CTNNB1 0
• CXCR4 0
• HDAC 0
• IL-1 0
• BDNF 0
• BRD4 0
• CD40 0
• DPP-4 0
• FTO 0
• HER2 0
• HMGB1 0
• KRAS 0
• MDM2 0
• METTL3 0
• PTEN 0
• RANKL 0
• TIGIT 0
• YAP 0
• ABL1 0
• AQP4 0
• BCMA 0
• CD38 0
• CDKN2A 0
• FAK 0
• FGFR 0
• G6PD 0
• HTT 0
• IL-13 0

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Pulmonary Hypertension in COPD : from Observation to Emerging Novel therapeutic Insights and eXploration (PHOENIX)

  Universitat Zurich· Zurich, Switzerland· EU contribution €292,119· until Dec 2028

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  CellCourier: programmable drug delivery via combinatorial cell targeting and generative design of tailored binding peptides

  Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Fuer Gesundheit und Umwelt Gmbh· Neuherberg, Germany· EU contribution €150,000· until Jun 2027

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-JU-RIA

  GUIDE-AI – Guiding your treatment with current evidence

  Charite - Universitaetsmedizin Berlin· Berlin, Germany· EU contribution €4,895,668· until Dec 2029· 8 countries

• European Commission (Horizon Europe) · HORIZON-ERC-SYG

  Smart Detectors for Darkfield X-ray Imaging (SmartX)

  Technische Universitaet Muenchen· Muenchen, Germany· EU contribution €10,840,961· until Mar 2031· 3 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  Development of an Advanced Airway-On-A-Chip Model to Investigate Neuronal Hypersensitivity in Chronic Cough (REVEAL)

  Universitaetsklinikum Aachen· Aachen, Germany· EU contribution €1,498,775· until Dec 2029

  The disease is named only in the funder's project summary, not in the title.

5 of 15 running projects, newest first. Listed amounts together: €50.5m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Trials whose registry record says individual participant data (IPD) will be shared.

No trial in this view states that it shares participant data.

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 27
• Organoids 7
• Mendelian Randomization Analysis 69
• CRISPR-Cas Systems 1
• Gene Expression Profiling 69
• Sequence Analysis, RNA 7
• Whole Genome Sequencing 4
• Proteomics 31
• Metabolomics 34
• Mass Spectrometry 6
• Flow Cytometry 5
• Immunohistochemistry 5
• Liquid Biopsy 2
• Circulating Tumor DNA 1
• Magnetic Resonance Imaging 32
• Machine Learning 103
• Deep Learning 33
• Cohort Studies 227
• Genome-Wide Association Study 72

• Circulating DNA-Markers of High Risk for Lung Cancer in Patients with Chronic Obstructive Pulmonary Disease.

  Bull Exp Biol Med, Jun 2026

• Expanding role of cell-free DNA for the early diagnosis and monitoring of pulmonary diseases.

  Chin Med J (Engl), Jan 2026

See which targets of this disease your abstract mentions, and go to the people working on them.